

**Supplementary Table 3.** Comparison of Demographic and Clinical Characteristics between Non-EBD Group and EBD Group

Variable	Non-EBD group (n = 66)	EBD group (n = 7)	P-value
Age at diagnosis (yr)	22.5 (13–68)	24.0 (15–30)	0.328
Sex, male:female	51:15	5:2	0.745
Body mass index (kg/m <sup>2</sup> )	20.6 (15.0–32.5)	21.5 (16.2–24.0)	0.775
Disease duration (yr)	5 (0–36)	13 (0–36)	0.081
Previous bowel resection	17 (25.8)	2 (28.6)	0.872
Perianal disease	26 (39.4)	4 (57.1)	0.364
Current smoking	14 (21.2)	4 (57.1)	0.036
Disease phenotype			
B1 (inflammatory)	30 (45.5)	1 (14.3)	0.113
B2 (stricturing)	22 (33.3)	5 (71.4)	0.047
B3 (penetrating)	14 (21.2)	1 (14.3)	0.667
Crohn's Disease Activity Index	72 (14–143)	54 (45–99)	0.296
Concomitant medication for CD			
Enteral nutrition	26 (39.4)	4 (57.1)	0.360
5-Aminosalicylic acid	36 (54.5)	4 (57.1)	0.896
Corticosteroid	2 (3.0)	0	0.641
Immunomodulator	12 (18.2)	1 (14.3)	0.798
Infliximab	24 (36.4)	2 (28.6)	0.862
Adalimumab	5 (7.6)	2 (28.6)	0.073
Ustekinumab	1 (1.5)	1 (14.3)	0.049
US-CD	8 (0–42)	13 (7–29)	0.036

Values are presented as median (range) or number (%).

EBD, endoscopic balloon dilation; CD, Crohn's disease; US, ultrasonography.

P-values were calculated using the Mann-Whitney *U* test for continuous variables and chi-square test for categorical data.